Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease refractory anemia
Phenotype C0026986|myelodysplastic syndrome
Sentences 11
PubMedID- 25428262 The splicing factor sf3b1 is the most commonly mutated gene in the myelodysplastic syndrome (mds), particularly in patients with refractory anemia with ring sideroblasts (rars).
PubMedID- 21226301 An 85-year-old woman, who had been given a diagnosis of myelodysplastic syndrome with refractory anemia 2 years previously and required blood transfusion once a month, was admitted with complaints of fever, general fatigue, and dry cough.
PubMedID- 24716056 Final diagnosis was high-grade myelodysplastic syndrome consistent with refractory anemia with excess blasts.
PubMedID- 20569983 We performed an open-labeled single-arm prospective phase ii clinical trial of vitamin k(2) (menatetrenone: vk2) monotherapy and vk2 plus 1alpha-hydroxyvitamin d(3) (alfacalcidol: vd3) combination therapy for myelodysplastic syndromes (mds) with refractory anemia and refractory cytopenia with multilineage dysplasia, having either low or intermediate-1 risks of the ipss.
PubMedID- 24958999 The goal of this study was to explore the plasma proteome of myelodysplastic syndrome (mds) patients with refractory anemia with excess blasts subtype 2 (raeb-2) in comparison to healthy controls.
PubMedID- 23897263 Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the fab classification.
PubMedID- 20052416 When we examined chk1 expression in this data set, we found it significantly decreased in patients suffering from myelodysplastic syndromes with refractory anemia with blasts [29] (figure 7b).
PubMedID- 26171179 The aim of this the study was to verify that biosimilar epoetin-alpha is similar in terms of efficacy, safety and cost to originator epoetin-alpha for the treatment of refractory anemia in patients with myelodysplastic syndrome.
PubMedID- 26493409 Since the patient refused bone marrow evaluation, she was initially treated with erythropoietin therapy based on the assumption that she may have an underlying refractory anemia associated with myelodysplastic syndrome or anemia of chronic disease.
PubMedID- 21434945 In many patients with refractory anemia associated with lower risk myelodysplastic syndromes and a 5q chromosome deletion, lenalidomide leads to transfusion independence, considerably improving quality of life.
PubMedID- 20037898 The findings were diagnostic of myelodysplastic syndrome with refractory anemia with excess of blasts in accordance with the world health organization criteria modified for pediatric age group.

Page: 1